Prostate Cancer Imaging

PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real Life

The purpose of the study is to provide pilot data on the clinical situations in which ordering a 18F-DCFPyL positron emission tomography/computed tomography (PET/CT) was thought to be clinically useful, and to document how the results of the 18F-DCFPyL PET/CT affected patient management. The results of this study could then serve as a guide to help OHIP to consider these scenarios when deciding the precise indications for funded 18F-DCFPyL PET/CT scans in the future. In this study the investigators will image subjects with prostate cancer using 18F-DCFPyL PET/CT and record how the result of the study affected patient management.

No pharmaceutical medication involved
Recruiting patients only

Diagnostic Test - 18F-DCFPyL PET/CT

A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push. After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v). Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL. At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base.

PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real Life